Divalproex Sodium Tablet, Film Coated, Extended Release
Product Images NDC 71610-205

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Divalproex Sodium (NDC 71610-205). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Aphena Pharma Solutions - Tennessee, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Bottle Label 500 mg (71610 0205 30)

Label for Divalproex Sodium extended-release tablets, 500 mg strength, supplied in bottles of 30 tablets. The label includes storage instructions to keep the product between 20-25 degrees Celsius and dispense in a tight, light-resistant container. Manufactured by Aurobindo Pharma Limited in Hyderabad, India, and repackaged by Aphena Pharma Solutions in Cookeville, TN. Contains barcodes and lot, expiration, and NDC details.*

FDA Label Image

Aphena Pharma Solutions (TN)

FDA Label Image

Figure 1 (Divalproex Fig1)

A cumulative percentage graph comparing the % reduction in CPS (Clinical Parameter Score) rate for patients treated with Divalproex Sodium Delayed-Release Tablets versus placebo. The x-axis shows % of patients from 100 to 0, and the y-axis shows % reduction in CPS rate ranging from -100% (worsening) to 100% (improvement). The solid line represents Divalproex Sodium, showing greater improvement compared to the dashed placebo line.*

FDA Label Image

Figure 2 (Divalproex Fig2)

A cumulative percentage plot comparing the percent reduction in CPS Rate against percent of patients for high dose and low dose Divalproex Sodium delayed-release tablets. The vertical axis shows improvement or worsening with a midpoint of no change, while the horizontal axis represents the percent of patients.*

FDA Label Image

Figure-3 (Divalproex Fig3)

A bar chart comparing the effect of placebo to Divalproex Sodium Extended-Release Tablets. The x-axis shows the two groups, placebo (white bar) and Divalproex Sodium Extended-Release Tablets (black bar). The y-axis likely represents a measured variable, with values indicating higher measurement for the Divalproex group. A significance notation p=0.006 is shown.*

FDA Label Image

Structure (Divalproex Str)

Chemical structure of divalproex sodium showing the polymeric form with sodium ions and valproic acid moieties. The diagram depicts the arrangement of carbon, hydrogen, oxygen, and sodium atoms in the compound.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.